Condition (MeSH)
Prion Diseases
ClinicalTrials.gov lists 30 trials for Prion Diseases or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
12 of the 30 trials are tagged with Prion Diseases itself; the rest are tagged with a narrower condition beneath it.
When did Prion Diseases trials start? (17)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 2 |
| 2024 | 3 |
| 2023 | 2 |
| 2022 | 3 |
| 2021 | 2 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 1 |
Showing 10 of 17 earlier years.
No forecast is made for this condition: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Prion Diseases trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 2 |
| Phase 2 | 3 |
| Phase 3 | 1 |
| Not applicable | 9 |
| Observational | 13 |
How many Prion Diseases trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 8 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 2 |
| Completed | 16 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Prion Diseases trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Faculty Hospital Kralovske Vinohrady | 1 |
| Ionis Pharmaceuticals, Inc. | 1 |
| Medical Research Council | 1 |
| NHS Blood and Transplant | 1 |
Which drugs are being tested for Prion Diseases? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Quinacrine | 2 |
| Efavirenz | 1 |
| ION717 | 1 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| [PRP] platelet rich plasma | 2 |
| No Interventions | 1 |
| NaCl 0.9% NS | 1 |
| PrP-siRNA | 1 |
| Hyaluronic Acid (HA) and Platelet rich plasma | 1 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Prion Diseases trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Death | 29 | 1 |
| Fall | 2 | 1 |
| Hemorrhage | 2 | 1 |
| Post-LP Dizziness | 2 | 1 |
| Post-LP headache | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Prion Diseases? (12)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Fluid Biomarkers in Individuals at Risk for Genetic Prion Disease up to Disease Conversion. | Neurology | 2024 | Yes |
| Mitochondrial dysfunction in preclinical genetic prion disease: A target for preventive treatment? | Neurobiology of disease | 2019 | Yes |
| Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. | Acta neuropathologica | 2013 | Yes |
| Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. | Proceedings of the National Academy of Sciences of the United States of America | 2001 | Yes |
| Binding of disease-associated prion protein to plasminogen. | Nature | 2000 | Yes |
Showing 5 of 12 publications.
Prevalence (4)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Human prion disease | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Human prion disease | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Human prion disease | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Human prion disease | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Human prion disease | 56970 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Human prion disease | 56970 | Exact | Orphadata Science knowledge files, Product 1 |
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.